MindMed to Present at Key September Investor Conferences

0.7 min readPublished On: September 12th, 2024By HCN News Team

LOS ANGELES- Mind Medicine (MindMed) Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for brain health disorders, announced its participation in three significant investor conferences in September 2024.

MindMed’s management team will engage in discussions on the evolving role of psychedelics in psychiatry and brain health treatments. The company’s schedule includes:

A panel discussion at the H.C. Wainwright Global Investment Conference on September 10.
A fireside chat at Baird’s Global Healthcare Conference on September 11.
A second fireside chat at the Cantor Global Healthcare Conference on September 17.

All events will take place in New York, and audio webcasts of the presentations will be accessible through MindMed’s Investor Relations website for 90 days post-event, allowing investors to review key company updates.

This participation underscores MindMed’s ongoing efforts to engage with the investment community and provide insights into its development of therapeutic options for brain health disorders.

About the Author: HCN News Team

The News Team at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. We cover capital markets, finance, branding, marketing and everything important in between. Most of all, we follow the money.